Huang Ying, Anderle Pascale, Bussey Kimberly J, Barbacioru Catalin, Shankavaram Uma, Dai Zunyan, Reinhold William C, Papp Audrey, Weinstein John N, Sadée Wolfgang
Program of Pharmacogenomics, Department of Pharmacology, College of Medicine and Public Health, The Ohio State University, Columbus, 43210, USA.
Cancer Res. 2004 Jun 15;64(12):4294-301. doi: 10.1158/0008-5472.CAN-03-3884.
Membrane transporters and channels (collectively the transportome) govern cellular influx and efflux of ions, nutrients, and drugs. We used oligonucleotide arrays to analyze gene expression of the transportome in 60 human cancer cell lines used by the National Cancer Institute for drug screening. Correlating gene expression with the potencies of 119 standard anticancer drugs identified known drug-transporter interactions and suggested novel ones. Folate, nucleoside, and amino acid transporters positively correlated with chemosensitivity to their respective drug substrates. We validated the positive correlation between SLC29A1 (nucleoside transporter ENT1) expression and potency of nucleoside analogues, azacytidine and inosine-glycodialdehyde. Application of an inhibitor of SLC29A1, nitrobenzylmercaptopurine ribonucleoside, significantly reduced the potency of these two drugs, indicating that SLC29A1 plays a role in cellular uptake. Three ABC efflux transporters (ABCB1, ABCC3, and ABCB5) showed significant negative correlations with multiple drugs, suggesting a mechanism of drug resistance. ABCB1 expression correlated negatively with potencies of 19 known ABCB1 substrates and with Baker's antifol and geldanamycin. Use of RNA interference reduced ABCB1 mRNA levels and concomitantly increased sensitivity to these two drugs, as expected for ABCB1 substrates. Similarly, specific silencing of ABCB5 by small interfering RNA increased sensitivity to several drugs in melanoma cells, implicating ABCB5 as a novel chemoresistance factor. Ion exchangers, ion channels, and subunits of proton and sodium pumps variably correlated with drug potency. This study identifies numerous potential drug-transporter relationships and supports a prominent role for membrane transport in determining chemosensitivity. Measurement of transporter gene expression may prove useful in predicting anticancer drug response.
膜转运蛋白和通道(统称为转运体组)控制着细胞对离子、营养物质和药物的摄取与外排。我们使用寡核苷酸阵列分析了美国国立癌症研究所用于药物筛选的60种人类癌细胞系中转运体组的基因表达情况。将基因表达与119种标准抗癌药物的效力进行关联,确定了已知的药物 - 转运体相互作用,并提示了新的相互作用。叶酸、核苷和氨基酸转运蛋白与它们各自药物底物的化学敏感性呈正相关。我们验证了溶质载体家族29成员A1(核苷转运体ENT1)的表达与核苷类似物阿扎胞苷和肌苷 - 糖二醛效力之间的正相关。应用溶质载体家族29成员A1的抑制剂硝基苄基巯基嘌呤核糖核苷,显著降低了这两种药物的效力,表明溶质载体家族29成员A1在细胞摄取中起作用。三种ATP结合盒(ABC)外排转运蛋白(ABCB1、ABCC3和ABCB5)与多种药物呈显著负相关,提示了一种耐药机制。ABCB1的表达与19种已知ABCB1底物的效力以及贝克抗叶酸剂和格尔德霉素呈负相关。使用RNA干扰降低ABCB1的mRNA水平,并随之增加了对这两种药物的敏感性,这正如ABCB1底物所预期的那样。同样,通过小干扰RNA特异性沉默ABCB5增加了黑色素瘤细胞对几种药物的敏感性,表明ABCB5是一种新的化疗耐药因子。离子交换体、离子通道以及质子和钠泵的亚基与药物效力的相关性各不相同。这项研究确定了众多潜在的药物 - 转运体关系,并支持膜转运在决定化学敏感性方面的重要作用。转运体基因表达的测定可能有助于预测抗癌药物反应。